Symbicort Turbohaler

Symbicort is a widely used prescription medication for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The brand was developed by the Anglo-Swedish pharmaceutical giant AstraZeneca. The Turbohaler device itself is a dry powder inhaler that was pioneered by the company's research and development teams.

While AstraZeneca is a global company with manufacturing sites worldwide, Symbicort is primarily produced in specialized facilities in Sweden and France for the European market. AstraZeneca serves as the ultimate owner, maintaining its headquarters in the United Kingdom. The brand remains a flagship product in their respiratory health portfolio.